Why Corporate Apparel Company Cintas Shares Are Gaining Today

Cintas Corporation shares surge as third-quarter earnings beat expectations, with robust revenue growth and raised annual outlook.

Cintas Corporation (NASDAQ:CTAS) shares are trading higher on Wednesday.

The company reported third-quarter earnings per share of $3.84, beating the analyst consensus of $3.58.

Quarterly revenue of $2.406 billion beat the street view of $2.386 billion. Revenues rose 9.9% year over year.

Gross profit for the third quarter was $1.19 billion, marking an increase of 14.9% year over year. Gross margin expanded to 49.4% compared to 47.2% in last year’s third quarter.

Operating income for the third quarter of fiscal 2024 increased 16.6% to $520.8 million.

Check This Out: Why Is NIO Stock Trading Lower Today?

Todd M. Schneider, Cintas’ President, and Chief Executive Officer, stated, “Each of our operating segments continue to execute at a high level, which led to robust revenue growth of 9.9%, record high gross margin of 49.4%, record high operating margin of 21.6% and diluted EPS growth of 22.3%.”

On March 15, 2024, Cintas paid an aggregate quarterly cash dividend of $137.6 million to shareholders, an increase of 17.1% from the amount paid last March.

Outlook: Cintas increased FY24 annual revenue expectations from $9.48 billion-$9.56 billion to $9.57 billion-$9.60 billion (estimate: $9.56 billion).

The firm raised EPS outlook from $14.35-$14.65 to $14.80-$15.00 (estimate: $14.60).

Price Action: CTAS shares are trading higher by 8.77% to $688.98 on the last check Wednesday.

Photo via Wikimedia Commons

Total
0
Shares
Related Posts
Read More

ARS Pharmaceuticals Submits Response For neffy Marketing Authorization Application To EMA’s CHMP And Enters License Agreement With CSL Seqirus For Commercialization Of neffy In Australia And New Zealand

CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat dose PK/PD study of

CSLLY